Rhenman & Partners Asset Management Ab Decreased Pfizer Inc (NYSE:PFE) Stake By $14.70 Million

October 13, 2017 - By Winifred Garcia

Investors sentiment decreased to 0.94 in Q2 2017. Its down 0.01, from 0.95 in 2017Q1. It turned negative, as 58 investors sold PFE shares while 716 reduced holdings. 112 funds opened positions while 612 raised stakes. 4.02 billion shares or 1.07% less from 4.06 billion shares in 2017Q1 were reported. Woodstock has 1.01% invested in Pfizer Inc. (NYSE:PFE). Harvest Capital Management owns 27,391 shares. Colonial Trust Advisors owns 27,822 shares for 0.21% of their portfolio. California State Teachers Retirement invested 0.81% of its portfolio in Pfizer Inc. (NYSE:PFE). Pacad Ltd has 63,231 shares for 0.31% of their portfolio. 8.70M are owned by Epoch Invest Prns. Milestone Group stated it has 0.13% of its portfolio in Pfizer Inc. (NYSE:PFE). Prudential reported 0.5% in Pfizer Inc. (NYSE:PFE). Mark Sheptoff Financial Planning Limited Com accumulated 44,698 shares or 1.03% of the stock. Freestone Capital Holding Llc invested 0.31% in Pfizer Inc. (NYSE:PFE). New York-based Boyar Asset Mgmt has invested 3.77% in Pfizer Inc. (NYSE:PFE). Keating Counselors owns 0.25% invested in Pfizer Inc. (NYSE:PFE) for 17,250 shares. Aviance Cap Llc reported 192,740 shares. Moors Cabot accumulated 183,079 shares. Signature Est And Inv Limited Co accumulated 6,430 shares.

Rhenman & Partners Asset Management Ab decreased its stake in Pfizer Inc (NYSE:PFE) by 97.58% based on its latest 2017Q3 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab sold 420,000 shares as the company’s stock declined 3.45% while stock markets rallied. The institutional investor held 10,422 shares of the health care company at the end of 2017Q3, valued at $372,000, down from 430,422 at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Pfizer Inc for a number of months, seems to be less bullish one the $216.41 billion market cap company. The stock declined 0.08% or $0.03 reaching $36.31 per share. About 12.77 million shares traded. Pfizer Inc. (NYSE:PFE) has declined 2.76% since October 14, 2016 and is downtrending. It has underperformed by 19.46% the S&P500.

Pfizer Inc. (NYSE:PFE) Ratings Coverage

Among 20 analysts covering Pfizer (NYSE:PFE), 8 have Buy rating, 1 Sell and 11 Hold. Therefore 40% are positive. Pfizer has $54.0 highest and $3300 lowest target. $38.63’s average target is 6.39% above currents $36.31 stock price. Pfizer had 59 analyst reports since July 29, 2015 according to SRatingsIntel. On Thursday, April 7 the stock rating was reinitiated by JP Morgan with “Overweight”. Credit Suisse downgraded the shares of PFE in report on Thursday, July 20 to “Neutral” rating. Argus Research maintained the shares of PFE in report on Wednesday, July 29 with “Buy” rating. The firm has “Buy” rating by Piper Jaffray given on Friday, August 14. Societe Generale maintained Pfizer Inc. (NYSE:PFE) on Friday, March 24 with “Neutral” rating. On Tuesday, October 20 the stock rating was upgraded by Cowen & Co to “Outperform”. The stock has “Overweight” rating by Piper Jaffray on Friday, August 28. Jefferies maintained Pfizer Inc. (NYSE:PFE) rating on Thursday, July 14. Jefferies has “Buy” rating and $41.50 target. Morgan Stanley upgraded it to “Overweight” rating and $38 target in Friday, October 2 report. The stock has “Hold” rating by BMO Capital Markets on Friday, April 28.

Pfizer Inc. is a research-based global biopharmaceutical company. The company has market cap of $216.41 billion. The Firm is engaged in the discovery, development and manufacture of healthcare products. It has a 26.47 P/E ratio. The Company’s global portfolio includes medicines and vaccines, as well as consumer healthcare products.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Bloomberg.com which released: “Pfizer Spins Off New Firm for Some Rare Disease Drugs” on September 25, 2017, also Bloomberg.com with their article: “Pfizer’s Big Deal Still Elusive as Company to Shed Consumer Unit” published on October 10, 2017, Seekingalpha.com published: “Pfizer’s Ibrance To Rally Share Price Past $40” on September 25, 2017. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Seekingalpha.com and their article: “Pfizer: A Good Buy” published on October 02, 2017 as well as Barrons.com‘s news article titled: “Pfizer Seen Mulling Options” with publication date: October 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.